As a core component of the m6A “writer” complex, METTL14 not only regulates the expression of immune checkpoint molecules such as PD-1 and PD-L1 to modulate T cell function and immune escape, but also interacts with multiple non-canonical signaling pathways, thereby profoundly influencing tumor sensitivity to immunotherapy. The gene discussed is METTL14; the disease is neoplasm.